BRIEF-RenovoRx Gets FDA Orphan Drug Designation For Oxaliplatin To Treat Pancreatic Cancer

RenovoRx, Inc.

RenovoRx, Inc.

RNXT

0.00

May 28 (Reuters) - RenovoRx Inc RNXT.O:

  • ANNOUNCES FDA ORPHAN DRUG DESIGNATION GRANTED: OXALIPLATIN FOR THE TREATMENT OF PANCREATIC CANCER

  • ODD PROVIDES SEVEN YEARS OF MARKET EXCLUSIVITY UPON FDA APPROVAL

  • TIGER-PAC TRIAL ENROLLMENT TO CLOSE JUNE 2026, FINAL DATA READOUT MID TO LATE 2027

Source text: ID:nGNXs853c

Further company coverage: RNXT.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.